In the context of gastric cancer peritoneal metastasis, ASO drug development often involves chemical modifications to improve efficacy.[44] For example, ASOs targeting the SYT13 gene have been modified using amido‐bridged nucleic acid (AmNA) technology to enhance their anti‐metastatic potential in gastric cancer.[45] In addition, research into mRNA vaccines is underway to identify new therapeutic targets for this condition. This evidence concerns the gene SYT13 and gastric cancer.